Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BBT enhances glucose-stimulated insulin secretion (GSIS) in compromised conditions, demonstrates anti-hyperglycemia effects, and shields β-cells from cytokine- or streptozotocin (STZ)-triggered apoptosis in type 2 diabetes models. Its mechanism of action involves the cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathways [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | BBT enhances glucose-stimulated insulin secretion (GSIS) in compromised conditions, demonstrates anti-hyperglycemia effects, and shields β-cells from cytokine- or streptozotocin (STZ)-triggered apoptosis in type 2 diabetes models. Its mechanism of action involves the cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathways [1]. |
Molecular Weight | 386.26 |
Formula | C18H12BrNO2S |
CAS No. | 445000-45-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BBT 445000-45-3 Membrane transporter/Ion channel Metabolism Calcium Channel inhibitor inhibit